Diagnosis and management of Sjögren syndrome.

Sjögren syndrome is a systemic autoimmune disease characterized by dry eyes and dry mouth. Other organ systems are affected in many patients. Sjogren syndrome is classified as primary or secondary. In primary disease, Sjogren syndrome is a solitary process, whereas secondary disease accompanies another autoimmune disease--often rheumatoid arthritis. Sjögren syndrome is a challenging diagnosis, requiring the family physician to coordinate with a team of specialists, including dentists, otolaryngologists, rheumatologists, and ophthalmologists. Pilocarpine and cevimeline can help relieve dry eyes and dry mouth.

[1]  M. Ramos-Casals,et al.  Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. , 2007, Rheumatology.

[2]  Cheng-Han Wu,et al.  Pilocarpine Hydrochloride for the Treatment of Xerostomia in Patients with Sjögren's Syndrome in Taiwan—A Double-blind, Placebo-controlled Trial , 2006, Journal of the Formosan Medical Association.

[3]  B. Burt.  The use of sorbitol- and xylitol-sweetened chewing gum in caries control. , 2006, Journal of the American Dental Association.

[4]  E. Zintzaras,et al.  The risk of lymphoma development in autoimmune diseases: a meta-analysis. , 2005, Archives of internal medicine.

[5]  P. Lipsky,et al.  Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy , 2005, Current opinion in rheumatology.

[6]  J. Sánchez-Guerrero,et al.  Prevalence of Sjögren's syndrome in ambulatory patients according to the American-European Consensus Group criteria. , 2005, Rheumatology.

[7]  A. Tzioufas,et al.  Primary Sjögren’s syndrome: new clinical and therapeutic concepts , 2004, Annals of the rheumatic diseases.

[8]  J. Yagüe,et al.  Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. , 2005, Rheumatology.

[9]  K. Tsubota,et al.  Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. , 2004, American journal of ophthalmology.

[10]  H. Moutsopoulos,et al.  Clinical manifestations and early diagnosis of Sjögren syndrome. , 2004, Archives of internal medicine.

[11]  J. Whitcher,et al.  Cataract Surgery , 1976, The Lancet.

[12]  L. Jacobsson,et al.  Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. , 2004, Arthritis and rheumatism.

[13]  G. Baron,et al.  Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). , 2004, Arthritis and rheumatism.

[14]  P. Voulgari,et al.  Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: a randomised 12 week controlled study , 2003, Annals of the rheumatic diseases.

[15]  G. Kammer,et al.  Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. , 2003, Arthritis and rheumatism.

[16]  C. Vitali.  Classification criteria for Sjögren’s syndrome , 2003, Annals of the rheumatic diseases.

[17]  M. García-Carrasco,et al.  Primary Sjögren Syndrome: Clinical and Immunologic Disease Patterns in a Cohort of 400 Patients , 2002, Medicine.

[18]  E. Tindall,et al.  Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. , 2002, Archives of internal medicine.

[19]  R. Jonsson,et al.  Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study , 2002, Annals of the rheumatic diseases.

[20]  J. Ioannidis,et al.  Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. , 2002, Arthritis and rheumatism.

[21]  J. Ship,et al.  Diagnosing, managing, and preventing salivary gland disorders. , 2002, Oral diseases.

[22]  I. Al-Hashimi,et al.  The management of Sjögren's syndrome in dental practice. , 2001, Journal of the American Dental Association.

[23]  S. Pillemer,et al.  Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. , 2001, Mayo Clinic proceedings.

[24]  S. Khuder,et al.  Frequency and predictive value of the clinical manifestations in Sjögren's syndrome. , 2001, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[25]  R. Fox,et al.  Update in Sjögren syndrome. , 2000, Current opinion in rheumatology.

[26]  J. Kim,et al.  The use of vital dyes in corneal disease. , 2000, Current opinion in ophthalmology.

[27]  J. Ioannidis,et al.  Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. , 2000, Seminars in arthritis and rheumatism.

[28]  Hannu Uusitalo,et al.  Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both) , 1999, Annals of the rheumatic diseases.

[29]  S R Carter,et al.  Eyelid disorders: diagnosis and management. , 1998, American family physician.

[30]  K. Shiozawa,et al.  Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[31]  A. Wu,et al.  Sjögren's syndrome. , 1994, Seminars in dermatology.

[32]  L. Sreebny,et al.  Xerostomia in Diabetes Mellitus , 1992, Diabetes Care.

[33]  A. Symonides,et al.  [Salivary gland enlargement in juvenile diabetes]. , 1972, Polski tygodnik lekarski.